Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Liquidia Corporation stock logo
LQDA
Liquidia
$56.40
-1.8%
$48.96
$22.31
▼
$93.61
$5.10B0.42.29 million shs459,041 shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$588.08
-0.5%
$542.60
$455.63
▼
$614.23
$25.05B0.49552,484 shs115,399 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Liquidia Corporation stock logo
LQDA
Liquidia
0.00%+29.30%+67.13%-26.11%+104.74%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
0.00%+5.19%+10.89%+16.26%+26.75%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Liquidia Corporation stock logo
LQDA
Liquidia
$56.40
-1.8%
$48.96
$22.31
▼
$93.61
$5.10B0.42.29 million shs459,041 shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$588.08
-0.5%
$542.60
$455.63
▼
$614.23
$25.05B0.49552,484 shs115,399 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Liquidia Corporation stock logo
LQDA
Liquidia
0.00%+29.30%+67.13%-26.11%+104.74%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
0.00%+5.19%+10.89%+16.26%+26.75%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Liquidia Corporation stock logo
LQDA
Liquidia
2.50
Moderate Buy$75.2333.40% Upside
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
2.69
Moderate Buy$676.4015.02% Upside

Current Analyst Ratings Breakdown

Latest UTHR and LQDA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Initiated CoverageBuy$76.00
11/12/2026
Liquidia Corporation stock logo
LQDA
Liquidia
UpgradeStrong Sell ➝ Hold
11/11/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Set Price TargetNeutral$54.00
11/11/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Boost Price TargetEqual Weight$33.00 ➝ $40.00
11/11/2026
Liquidia Corporation stock logo
LQDA
Liquidia
UpgradeOutperform ➝ Strong-Buy$53.00 ➝ $77.00
11/11/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Boost Price TargetBuy$58.00 ➝ $66.00
11/10/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Boost Price TargetBuy$55.00 ➝ $62.00
11/10/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Boost Price TargetBuy$70.00 ➝ $87.00
11/9/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
DowngradeBuy (B-) ➝ Hold (C+)
11/9/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Initiated CoverageBuy$660.00
11/5/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Boost Price TargetOverweight$700.00 ➝ $703.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Liquidia Corporation stock logo
LQDA
Liquidia
$158.32M32.10N/AN/A$0.51 per share110.58
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$3.18B7.87$32.82 per share17.92$164.81 per share3.57
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Liquidia Corporation stock logo
LQDA
Liquidia
-$68.92M-$1.23N/A14.39N/A-15.15%264.65%44.19%N/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$1.33B$26.5022.1918.353.9338.61%19.18%17.07%N/A

Latest UTHR and LQDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
Liquidia Corporation stock logo
LQDA
Liquidia
$0.96-$2.64-$3.60-$2.64$214.18 million$225.30 million
11/4/2026Q3 2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$6.01$5.71-$0.30$5.71$781.14 million$832.50 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Liquidia Corporation stock logo
LQDA
Liquidia
N/AN/AN/AN/AN/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Liquidia Corporation stock logo
LQDA
Liquidia
0.63
1.02
0.96
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/A
4.61
4.29

Institutional Ownership

CompanyInstitutional Ownership
Liquidia Corporation stock logo
LQDA
Liquidia
64.54%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
94.08%

Insider Ownership

CompanyInsider Ownership
Liquidia Corporation stock logo
LQDA
Liquidia
25.60%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
8.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Liquidia Corporation stock logo
LQDA
Liquidia
21690.11 million67.04 millionOptionable
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
1,40042.59 million38.93 millionOptionable

Recent News About These Companies

FY2026 Earnings Forecast for UTHR Issued By HC Wainwright
Analysts Issue Forecasts for UTHR FY2026 Earnings
HC Wainwright Initiates Coverage on United Therapeutics (NASDAQ:UTHR)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Liquidia stock logo

Liquidia NASDAQ:LQDA

$56.29 -1.12 (-1.95%)
As of 11:39 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

United Therapeutics stock logo

United Therapeutics NASDAQ:UTHR

$588.08 -3.08 (-0.52%)
As of 11:39 AM Eastern
This is a fair market value price provided by Massive. Learn more.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.